ArticleMolecular genetics & genomic medicine2026
Identification and Functional Analysis of a Novel NSD2 Missense Variant in a Patient With Rauch-Steindl Syndrome.
Article in Molecular genetics & genomic medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Correction to "Identification and Functional Analysis of a Novel NSD2 Missense Variant in a Patient With Rauch-Steindl Syndrome".Molecular genetics & genomic medicine · 2026Article
- Identification and Functional Analysis of a Novel NSD2 Missense Variant in a Patient With Rauch-Steindl Syndrome.Molecular genetics & genomic medicine · 2026Article
Corrections and comments
- Erratum issued
Authors and funding
8 authors.
Funding
Abstract
backgroundRauch-Steindl syndrome (RAUST) is a rare neurodevelopmental disorder caused by pathogenic variants in NSD2, a histone methyltransferase gene at 4p16.3. Due to phenotypic overlap with Wolf-Hirschhorn syndrome (WHS), RAUST is often misdiagnosed. Missense variants in NSD2 are particularly challenging to interpret without functional validation.
methodsGenomic DNA from the proband and her parents was extracted from peripheral blood. Trio-whole-exome sequencing (WES) was performed to identify candidate variants based on the clinical phenotype, followed by Sanger sequencing validation. RNA splicing impact was assessed via reverse transcription PCR and TA-cloning from peripheral blood mononuclear cells.
resultsA 7-year-8-month-old girl mainly presented with intrauterine and postnatal growth restriction, global developmental delay, intellectual disability, epilepsy, short stature, and facial dysmorphism was documented. Trio-WES identified a novel de novo missense variant in NSD2 (NM_001042424.3: c.2137G>C, p.Gly713Arg), which is located at the last base of exon 11 and was predicted to be highly likely to cause aberrant splicing. Functional analysis revealed this variant causes exon 11 skipping in 53% of transcripts, resulting in a frameshift (p.Leu672Glyfs*20) and premature truncation.
conclusionThis is the first report of an NSD2 missense variant that functionally acts as a splicing mutation leading to protein truncation. Our findings highlight the necessity of RNA-level functional assays for accurate variant interpretation and reinforce genotype-phenotype distinctions between RAUST and WHS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.